Carvedilol
Product Images NDC 53808-0859

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 53808-0859). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label-principal Display Panel (12.5 mg)

The image shows a packaging label for Carvedilol tablets with a strength of 12.5 mg. It is marked RX Only and labeled by Aurobindo. The package is indicated as being packed by DOH Central Pharmacy, Tallahassee, FL 32304. The label also displays an expiration date and barcode with UPC 365862144010.*

FDA Label Image

Package Label-principal Display Panel (25 mg)

Packaging label for Carvedilol 25 mg tablets. The label includes dispensing information indicating it is prescription only (RX Only) and shows packaging by DOH Central Pharmacy, Tallahassee, FL 32304. The label also features a lot number and UPC barcode.*

FDA Label Image

Package Label-principal Display Panel (3.125 mg)

Label for Carvedilol 3.125 mg tablets from State of Florida DOH Central Pharmacy. It includes lot number, expiration date, and a UPC barcode. The label lists the manufacturer as Aurobindo and provides the location Tallahassee, FL 32304.*

FDA Label Image

Package Label-principal Display Panel (6.25 mg)

Carvedilol 6.25 mg tablets label showing the product name and strength, quantity of 6.25 mg tablets, labeled for Rx use only. Manufactured by Aurobindo, packaged by DOH Central Pharmacy, Tallahassee, FL 32304. The label also includes a lot number and UPC barcode.*

FDA Label Image

Figure 1. Survival Analysis For Capricorn (intent-to-treat) (Carvedilol Fig1)

A line graph showing percentage mortality over 24 months comparing Carvedilol and Placebo groups. The y-axis represents % Mortality, and the x-axis shows time in months. The Carvedilol group shows consistently lower mortality than the Placebo group, with a P-value of 0.03 indicating statistical significance.*

FDA Label Image

Figure 2. Effects On Mortality For Subgroups In Capricorn (Carvedilol Fig2)

A forest plot displaying hazard ratios for various subgroups based on factors such as age, sex, prior conditions, and treatments after myocardial infarction (MI). The x-axis shows hazard ratios from 0.4 to 1.3. Subgroups compared include age under and over 70, men and women, timing of randomization post-MI, prior beta-blocker use, Killip classifications, thrombolytic therapy, PTCA treatment, presence of congestive heart failure, use of diuretics during MI, angina, hypertension, diabetes, heart rate categories, systolic blood pressure, and an all patients group.*

FDA Label Image

Carvedilol Structure (Carvedilol Str)

Chemical structure diagram of carvedilol, showing its molecular composition with distinct aromatic rings and functional groups characteristic of the active ingredient carvedilol.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.